\
&
Contact us
\
&
Contact us
Pick a topic from the menu to get started.
NCP Flanders advisors explain the basic aspects of Horizon Europe - the EU’s key funding programme for research and innovation.
The programme:
Target audience: every stakeholder in Flanders interested as well from private companies as from research and higher educations institutes, governmental services and non-profit organisations, who has limited experience with Horizon 2020/Europe.
Pick a topic from the menu to get started.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
